Cutaneous melanoma, historically a rare disease, has continued to see increased incidence over the past several decades. Fortunately, this has been accompanied by increased understanding of the pathobiology, leading to the development of immunotherapy and targeted therapies. In this activity, melanoma specialist Jason J. Luke, MD, FACP, discusses the impact of evolving therapies on the disease burden, survival, and treatment tolerability by patients with cutaneous melanoma. Recent clinical trial results and guideline updates for both perioperative and metastatic cutaneous melanoma are reviewed. To provide patient-centric care, Dr. Luke shares his expert insights and recommendations for individualizing treatment selection and sequencing, as well as providing supportive care and adverse event management.
0.5 AMA PRA Category 1 CreditsTM
This activity is intended for medical oncologists, dermatologists, surgeons, and other clinicians who care for people with or at risk for cutaneous melanoma.
This activity is supported by an educational grant from Bristol Myers Squibb.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Content PlannersChris Elder, PharmD, BCOP (Medical Writer)
Advisory Board: Eisai, Genentech, Mirati, Novartis, Pfizer, Pharmacosmos, Sanofi
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
Jason J. Luke, MD, FACP
Associate Professor of Medicine
Director of Cancer Immunotherapeutics Center
University of Pittsburgh School of Medicine
- Identify molecular treatment targets for melanoma
- Compare various treatment considerations for adjuvant/neoadjuvant therapy in early-stage melanoma
- Create individualized, guideline-recommended treatment strategies, including sequencing considerations, for frontline and later lines of therapy in patients with metastatic melanoma
Jason J. Luke, MD, FACP
Advisory Board: (no stock) 7 Hills, Affivant, BioCytics, Bright Peak, Exo, F-star, Inzen, RefleXion, Xilio (stock) Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Kanaph, Mavu, NeoTX, OncAI, OncoNano, physIQ, Pyxis, Saros, STipe, Tempest
Consultant: AbbVie, Agenus, Alnylam, AstraZeneca, Atomwise, Bayer, Bristol Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Eisai, EMD Serono, Endeavor, Flame, G1 Therapeutics, Genentech, Gilead, Glenmark, HotSpot, Ikena, Immatics, Immunocore, IO Biotech, Incyte, Instil, Inzen, Janssen, Kadmon, KoBioLabs, Krystal, KSQ, LegoChem, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Pioneering Medicines, PsiOxus, Regeneron, Replimmune, Ribon, Roivant, Servier, Stingthera, Sumoitomo, Synlogic, Synthekine, Teva
Data and Safety Monitoring Board (DSMB): AbbVie, Agenus, Evaxion, Immutep
Research Support: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Hot Spot, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Novartis, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor